Gene silencing via genome editing

By employing site-specific nucleases to induce DNA inversions and rearrangements, the method addresses inefficiencies in traditional gene silencing, achieving stable and efficient gene expression modulation in plants.

JP2024166200AInactive Publication Date: 2024-11-28SYNGENTA CROP PROTECITON AG
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024131763
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-12-04
Filing Date
2024-08-08
Publication Date
2024-11-28
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Traditional gene silencing methods in plants, such as transgenic overexpression of sense RNA transcripts, hairpin transcripts, and antisense RNA, face inefficiencies and leaks due to mismatched expression in tissue and developmental stages, and genome editing for gene silencing has not been widely utilized.

Method used

Introduce site-specific nucleases like meganucleases, zinc finger nucleases, and Cas9 nucleases to create double-strand breaks in target genes, followed by DNA inversion to reduce gene expression, and utilize chromosomal rearrangements like deletions, duplications, and inversions to alter gene expression.

Benefits of technology

Achieves stable and efficient gene silencing and expression modulation by creating targeted chromosomal rearrangements, applicable to haploid, diploid, or polyploid genomes, including plants, with reduced expression of dominant, recessive, or semi-dominant genes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024166200000001_ABST
    Figure 2024166200000001_ABST
Patent Text Reader

Abstract

To provide methods and compositions for gene silencing by genome editing.SOLUTION: Nucleases are provided selected from the group consisting of meganucleases (MNs), zinc-finger nucleases (ZFNs), transcription-activator like effector nucleases (TALENs), Cas9 nuclease, Cfp1 nuclease, dCas9-FokI, dCpf1-FokI, chimeric Cas9 / Cpf1-cytidine deaminase, chimeric Cas9 / Cpf1-adenine deaminase, chimeric FEN1-FokI, and Mega-TALs, a nickase Cas9 (nCas9), chimeric dCas9 non-FokI nuclease and dCpf1 non-FokI nuclease. Additionally, the present invention relates to methods and compositions for gene silencing by genome editing. Also provided are methods and compositions for rearranging a chromosome by genome editing.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of PCT / CN2018 / 119155, filed December 4, 2018, which is incorporated by reference in its entirety.

[0002] Sequence Listing A Sequence Listing in ASCII text format, 47 kilobytes in size, submitted under 37 C.FR § 1.821, entitled "81724_ST25.txt", generated on November 19, 2018. This Sequence Listing is incorporated herein by reference for its disclosure.

[0003] The present invention relates to methods and compositions for gene silencing by genome editing or chromosomal rearrangement by genome editing. [Background technology]

[0004] Gene silencing is an important tool for studying gene function and delivering important traits to crop plants. Traditional strategies for gene silencing in plants include (Cold Spring Harb Symp Quant Biol.2006;71:481-5), transgenic overexpression of sense RNA transcripts, transgenic expression of hairpin transcripts, and transgenic expression of antisense RNA transcripts. Meanwhile, these techniques have some limitations. For the overproduced sense transcripts, the transcripts must not have premature termination codons, otherwise the efficiency is not sufficient and stable. In hairpin and antisense designs, it is impossible to match the expression of silencing RNA with the natural target mRNA in the same tissue and at the same developmental stage, so there is leakage in the RNA silencing effect.

[0005] The present disclosure provides a novel gene silencing method using genome editing to create chromosome inversion.Genome editing has not been used in gene silencing, except for placing transcriptional regulators close to the promoter of the gene to be silenced, as in WO18057863, WO2017180915 and WO2017023974. Summary of the Invention [Means for solving the problem]

[0006] The present disclosure provides a method for reducing expression of a target gene, the method comprising introducing into a cell a nuclease capable of site-specific DNA cleavage at a target genomic site, creating two or more double-stranded breaks in a single target gene, selecting cells in which the double-stranded breaks have been repaired with mediated DNA inversions, and reducing expression of the target gene. In some embodiments, the nuclease is selected from the group consisting of meganuclease (MN), zinc finger nuclease (ZFN), transcription activator-like effector nuclease (TALEN), Cas9 nuclease, Cfp1 nuclease, dCas9-FokI, dCpf1-FokI, chimeric Cas9 / Cpf1-cytidine deaminase, chimeric Cas9 / Cpf1-adenine deaminase, chimeric FEN1-FokI, and Mega-TAL, nickase Cas9 (nCas9), chimeric dCas9 non-FokI nuclease, and dCpf1 non-FokI nuclease. In some embodiments of the method, the double-stranded break in the target gene is located in a promoter, UTR, exon, intron, or gene-gene junction region. These methods can be used when the cell has a haploid, diploid, polyploid, or hexiploid genome. These methods can be used when the target gene is dominant, recessive, or semi-dominant. In some embodiments, the method can utilize one, two, or more guide sequences. This method is useful in plant cells, but is applicable to any cell.

[0007] The present disclosure provides a method for rearrangement of chromosomes by genome editing, the method includes generating at least one break in a chromosome by a site-specific nuclease and selecting the chromosome with rearrangement. In some embodiments, the method can utilize a site-specific nuclease selected from the group consisting of meganuclease (MN), zinc finger nuclease (ZFN), transcription activator-like effector nuclease (TALEN), Cas9 nuclease, Cfp1 nuclease, dCas9-FokI, dCpf1-FokI, chimeric Cas9 / Cpf1-cytidine deaminase, chimeric Cas9 / Cpf1-adenine deaminase, chimeric FEN1-FokI, and Mega-TAL, nickase Cas9 (nCas9), chimeric dCas9 non-FokI nuclease, and dCpf1 non-FokI nuclease. In some embodiments of the method, the chromosomal rearrangement comprises a deletion, a duplication, an inversion, or a translocation. In some embodiments of the method, the chromosomal rearrangement causes alteration of gene expression. In some embodiments of the method, the alteration of gene expression comprises regulation at the precursor mRNA level, or at the mature mRNA level, or at the translation level. In some embodiments of the method, the chromosomal rearrangement comprises chromosomes from two species, where the chromosomes can be grouped into one nucleus, such as in an interspecies hybrid. In some embodiments of the method, the chromosomal rearrangement results in new allele generation by fusing at least two alleles or two components from different alleles. In some embodiments of the method, the chromosomal rearrangement targets a promoter, an exon, an intron, or a transcription terminator. In some embodiments of the method, the chromosomal rearrangement causes alteration of gene expression of a different gene that has sequence similarity with the rearranged gene. In further embodiments of the method, the deletion, duplication, inversion, or translocation is 19 base pairs or more. [Brief description of the drawings]

[0008] [Figure 1]Graphical representation of a transformation event using construct 22602 (left), where two edits in exon 5 resulted in a deletion in event RIET142202A130A or an inversion in event RIET142202A049A, and a representation of a transformation event using construct 22604 (right), where two edits in exon 5 resulted in a deletion in event RIET142300A014A or an inversion in event RIET142500B024A049A. [Diagram 2] 1 shows a workflow for measuring expression of DEP1 from the endogenous locus. [Diagram 3] Gel electrophoresis of PCR products from genotyping of T1 seeds from event RIET142202A130A. [Figure 4] A wild-type rice plant next to a plant carrying a deletion in DEP1. [Diagram 5] 2–3 cm of rice plants sampled for RNA isolation. [Figure 6] Gel electrophoresis of rtPCR products from FI plants 17SBC500140, 17SBC500143, 17SBC500146, and 17SBC500149. [Figure 7] Graphical representation of exon 5 of DEP1 in F1 plants carrying deletions or insertions (top) and rtPCR products separated by gel electrophoresis (bottom). DEP1 products were quantified and normalized to the expression ratio of the rice ubiquitin gene OS03g0234200. [Figure 8] Graphical representation of exon 5 of DEP1 from the E0 plant, RIET142500A084A, identified in two translocations. [Figure 9] Schematic showing how two or more genome editing targets can be used to select for chromosomal translocations and duplications. [Figure 10] Schematic showing how inversions can lead to gene silencing. [Figure 11]FIG. 1 is a schematic showing how silencing by chromosomal inversion can be used to silence gene orthologs in hexaploid or polyploid genomes. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0009] Brief description of the sequences in the sequence listing SEQ ID NO:1 is the coding sequence for DENSE AND ERECT PANICLE 1

[0010] SEQ ID NO:2 is the gRNA-B and gRNA-D expression cassette from vector 22603

[0011] SEQ ID NO:3 is guide RNA-B targeting exon 5 of DEP1

[0012] SEQ ID NO:4 is gRNA-D, which also targets exon 5

[0013] SEQ ID NO:5 is 22604 gRNA-A, gRNA-D, gRNA-B, and gRNA-C

[0014] SEQ ID NO:6 is guide RNA-A

[0015] SEQ ID NO: 7 is guide RNA-C

[0016] SEQ ID NO:8 is a CAS9 expression cassette

[0017] SEQ ID NO:9 is the CAS9 Taqman assay forward primer

[0018] SEQ ID NO: 10 is the CAS9 Taqman assay reverse primer

[0019] SEQ ID NO:11 is the CAS9 Taqman assay probe

[0020] SEQ ID NO: 12 is the gRNA-A Taqman assay forward primer

[0021] SEQ ID NO: 13 is the gRNA-A Taqman assay reverse primer

[0022] SEQ ID NO: 14 is the gRNA-A Taqman assay probe

[0023] SEQ ID NO: 15 is the gRNA-C Taqman assay forward primer

[0024] SEQ ID NO: 16 is the gRNA-C Taqman assay reverse primer

[0025] SEQ ID NO: 17 is the gRNA-C Taqman assay probe

[0026] SEQ ID NO: 18 is the gRNA-D Taqman assay forward primer

[0027] SEQ ID NO: 19 is the gRNA-D Taqman assay reverse primer

[0028] SEQ ID NO:20 is the gRNA-D Taqman assay probe

[0029] SEQ ID NO:21 is DEP1 PCR primer 1

[0030] SEQ ID NO:22 is DEP1 PCR primer 2

[0031] SEQ ID NO:23 is an inversion between RNA-A and RNA-B

[0032] SEQ ID NO:24 is the deletion between gRNA-B and gRNA-D

[0033] SEQ ID NO: 25 is an inversion between gRNA-A and gRNA-B

[0034] SEQ ID NO: 26 is RIET142300A014A selected as an expression control

[0035] SEQ ID NO:27 is the sense genotyping primer for 14SBC500773

[0036] SEQ ID NO:28 is the antisense genotyping primer for 14SBC500773

[0037] SEQ ID NO:29 is the DEP1 qRT-PCR sense primer located in exon 1

[0038] SEQ ID NO:30 is a DEP1 qRT-PCR antisense primer located in the 3'UTR

[0039] SEQ ID NO:31 is rice ubiquitin (Os03g0234200) qRT-PCR primer 1

[0040] SEQ ID NO: 32 is rice ubiquitin (Os03g0234200) qRT-PCR primer 2

[0041] SEQ ID NO: 33 is wild type DEP1 qRT-PCR primer 1

[0042] SEQ ID NO: 34 is wild type DEP1 qRT-PCR primer 2

[0043] SEQ ID NO: 35 is a translocation between gRNA-A and gRNA-B, gRNA-C and gRNA-D

[0044] This description is not intended to be a detailed catalog of all the different ways in which the invention can be implemented or all the features that can be added to the invention. For example, features shown in connection with one embodiment may be incorporated in other embodiments, and features shown in connection with a particular embodiment may be omitted from that embodiment. In addition, numerous variations and additions to the various embodiments suggested herein will be apparent to those of skill in the art in light of this disclosure, and do not depart from the invention. Thus, the following description is intended to illustrate some specific embodiments of the invention, and is not intended to exhaustively identify all permutations, combinations, and variations thereof.

[0045] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which the present invention belongs. The terms used in the description of the present invention herein are only for describing specific embodiments and are not intended to limit the present invention. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety.

[0046] The following definitions and methods are provided to better define the present invention and to guide those of skill in the art in the practice of the present invention. Unless otherwise specified, terms used herein should be understood according to conventional usage by those of skill in the relevant art. Definitions of common terms in molecular biology are provided in Rieger et al., Glossary of Genetics: Classical and Molecular, 5 th edition, Springer-Verlag: New York, 1994.

[0047] As used in describing the embodiments of this invention and the appended claims, the singular forms "a," "an," and "the" are intended to include the plural forms as well, unless the context clearly dictates otherwise.

[0048] As used herein, "and / or" refers to and includes any and all possible combinations of one or more of the associated listed items.

[0049] The term "about," as used herein, when referring to a measurable value such as an amount of a compound, a dosage, a time, a temperature, and the like, is meant to encompass variations of 20%, 10%, 5%, 1%, 0.5%, or even 0.1% of the particular amount.

[0050] The terms "comprise" and / or "comprising" as used herein specify the presence of stated features, integers, steps, operations, elements, and / or components, but do not exclude the presence or addition of one or more other features, integers, steps, operations, elements, components, and / or groups thereof.

[0051] As used herein, the transitional phrase "consisting essentially of" means that the scope of the claim is to be interpreted to include the particular materials or steps recited in the claim, as well as those that do not materially affect the basic and novel characteristics of the claimed invention. Thus, the term "consisting essentially of" when used in the claims of the present invention is not intended to be interpreted as the equivalent of "comprising."

[0052] As used herein, the term "amplified" refers to the construction of multiple copies of a nucleic acid molecule or multiple copies of a complementary nucleic acid molecule using at least one of the nucleic acid molecules as a template. See, e.g., Diagnostic Molecular Microbiology: Principles and Applications, DH Persing et al., Ed., American Society for Microbiology, Washington, DC (1993). The product of amplification is called an amplicon.

[0053] A "coding sequence" is a nucleic acid sequence that is transcribed into RNA, such as mRNA, rRNA, tRNA, snRNA, sense RNA or antisense RNA. In some embodiments, the RNA is then translated in an organism to produce a protein.

[0054] As used herein, the term transgenic "event" refers to a recombinant plant produced by transformation and regeneration of a single plant cell with heterologous DNA, e.g., an expression cassette containing one or more genes of interest (e.g., transgenes). The term "event" refers to the original transformant and / or progeny of the transformant containing the heterologous DNA. The term "event" also refers to progeny produced by sexual outcrossing between a transformant and another line. Even after repeated backcrossing to the recurrent parent, the inserted DNA and the adjacent DNA from the transformed parent are present in the progeny of the cross at the same chromosomal location. Usually, transformation of plant tissue produces multiple events, each of which represents the insertion of a DNA construct into a different location in the genome of the plant cell. A particular event is selected based on the expression of the transgene or other desirable characteristics. Thus, as used herein, "MIR604 event," "MIR604," or "MIR604 event" refers to the original MIR604 transformant and / or progeny of the MIR604 transformant (U.S. Pat. Nos. 7,361,813, 7,897,748, 8,354,519, and 8,884,102, which are incorporated herein by reference).

[0055] As used herein, "expression cassette" refers to a nucleic acid molecule capable of directing the expression of a particular nucleotide sequence in a suitable host cell, and includes a promoter operably linked to a nucleotide sequence of interest (typically a coding region), which is operably linked to a termination signal. An expression cassette also typically includes sequences necessary for proper translation of the nucleotide sequence. The coding region usually codes for a protein of interest, but may also code for a functional RNA of interest, such as an antisense RNA, or a non-translated RNA, in a sense or antisense orientation. An expression cassette may also include sequences that are not necessary for the direct expression of the nucleotide sequence of interest, but are present for convenient restriction sites for removal of the cassette from the expression vector. An expression cassette containing a nucleotide sequence of interest may be chimeric, meaning that at least one of its components is heterologous with respect to at least one of the other components. An expression cassette may also be naturally occurring but obtained in a recombinant form useful for heterologous expression. Typically, however, the expression cassette is heterologous to the host, i.e., the particular nucleic acid sequence of the expression cassette does not naturally occur in the host cell and must have been introduced into the host cell or an ancestor of the host cell by a transformation process known in the art. Expression of the nucleotide sequence in the expression cassette may be under the control of a constitutive promoter or an inducible promoter that initiates transcription only when the host cell is exposed to some particular external stimulus. In the case of multicellular organisms such as plants, the promoter may also be specific to a particular tissue, or organ, or developmental stage. The expression cassette or a fragment thereof, when transformed into a plant, may also be referred to as an "inserted sequence" or "inserted sequence".

[0056] A "gene" is a defined region located in a genome that contains, in addition to the aforementioned coding nucleic acid sequence, other primarily regulatory nucleic acid sequences involved in the control of expression of the coding portion, i.e., transcription and translation. A gene may contain both coding and non-coding regions (e.g., introns, regulatory elements, promoters, enhancers, termination sequences, and 5' and 3' untranslated regions). A gene typically expresses a specific protein, including an mRNA, a functional RNA, or a regulatory sequence. A gene may or may not be used to produce a functional protein. In some embodiments, a gene refers to only the coding region. The term "native gene" refers to a gene as found in nature. The term "chimeric gene" refers to any gene that 1) contains a DNA sequence that contains regulatory and coding sequences that are not found together in nature, or 2) contains a sequence that codes for a portion of a protein that is not naturally adjacent, or 3) contains a portion of a promoter that is not naturally adjacent. Thus, a chimeric gene may contain regulatory and coding sequences that are derived from different sources, or regulatory and coding sequences that are derived from the same source but arranged in a manner different from that found in nature. A gene may be "isolated," which refers to a nucleic acid molecule that is substantially or essentially free from components that are normally found associated with the nucleic acid molecule in its natural state, including other cellular material, culture medium from recombinant production, and / or various chemicals used in chemically synthesizing the nucleic acid molecule.

[0057] The terms "express" or "expression" of a polynucleotide coding sequence means that the sequence is transcribed and optionally translated.

[0058] "Gene of interest," "nucleotide sequence of interest," or "sequence of interest" refers to any gene that, when transferred into a plant, confers a desired characteristic to the plant, such as antibiotic resistance, viral resistance, insect resistance, disease resistance, or resistance to other pests, herbicide resistance, improved nutritional value, improved performance in an industrial process, or altered reproductive performance. A "gene of interest" may also be one that is transferred to a plant to produce a commercially valuable enzyme or metabolite in the plant.

[0059] As used herein, "heterologous" refers to a nucleic acid molecule or nucleotide sequence that is not naturally associated with the host cell into which it is introduced, whether it is from another species or from the same species or organism but modified from its original form or form predominantly expressed in the cell (including non-naturally occurring multiple copies of a naturally occurring nucleic acid sequence). Thus, a nucleotide sequence that is from an organism or species different from that of the cell into which the nucleotide sequence is introduced is heterologous with respect to that cell and the progeny of the cell. In addition, heterologous nucleotide sequences include nucleotide sequences that are from the same natural original cell type and are inserted, but are present in a non-natural state (e.g., present in different copy numbers) and / or are under the control of regulatory sequences different from those found in the natural state of the nucleic acid molecule. A nucleic acid sequence can also be heterologous to other nucleic acid sequences with which it may be associated, for example, in a nucleic acid construct such as an expression vector. As a non-limiting example, a promoter can be present in a nucleic acid construct in combination with one or more regulatory elements and / or coding sequences that are not naturally occurring in association with that particular promoter, i.e., heterologous to the promoter.

[0060] A "homologous" nucleic acid sequence is a nucleic acid sequence that is naturally associated with the host cell into which it is introduced. A homologous nucleic acid sequence may also be a nucleic acid sequence that is naturally associated with another nucleic acid sequence that may be present, for example, in a nucleic acid construct. As a non-limiting example, a promoter may be present in a nucleic acid construct in combination with one or more regulatory elements and / or coding sequences that are naturally associated with that particular promoter, i.e., that are homologous to the promoter.

[0061] "Operably linked" refers to the association of nucleic acid sequences on a single nucleic acid sequence such that the function of one affects the function of the other. For example, a promoter is operably linked to a coding sequence or functional RNA if it can affect the expression of that coding sequence or functional RNA (i.e., the coding sequence or functional RNA is under the transcriptional control of the promoter). A coding sequence in a sense or antisense orientation can be operably linked to a regulatory sequence. Thus, a regulatory or control sequence (e.g., a promoter) operably associated with a nucleotide sequence can affect the expression of the nucleotide sequence. For example, a promoter operably linked to a nucleotide sequence encoding GFP can affect the expression of the GFP nucleotide sequence.

[0062] Control sequences need not be contiguous with the nucleotide sequence of interest, so long as they function to direct its expression. Thus, for example, intervening untranslated but transcribed sequences can be present between the promoter and the coding sequence and the promoter sequence can still be considered "operably linked" to the coding sequence.

[0063] As used herein, a "primer" is an isolated nucleic acid that is annealed to a complementary target DNA strand by nucleic acid hybridization to form a hybrid between the primer and the target DNA strand, and then extended along the target DNA strand by a polymerase, such as a DNA polymerase. Primer pairs or sets can be used, for example, for amplification of nucleic acid molecules by polymerase chain reaction (PCR) or other nucleic acid amplification methods.

[0064] A "probe" is an isolated nucleic acid molecule that is complementary to a portion of a target nucleic acid molecule and is typically used to detect and / or quantify the target nucleic acid molecule. Thus, in some embodiments, a probe can be an isolated nucleic acid molecule to which a detectable moiety or reporter molecule (e.g., a radioisotope, a ligand, a chemiluminescent agent, a fluorescent agent, or an enzyme) is attached. Probes according to the invention can include not only deoxyribonucleic acid or ribonucleic acid, but also polyamide and other probe materials that can specifically bind to a target nucleic acid sequence and be used to detect the presence and / or quantify the amount of the target nucleic acid sequence.

[0065] TaqMan probes are designed to anneal within the DNA region amplified by a particular primer set. As Taq polymerase extends the primers and synthesizes the nascent strand 3' to 5' of the complementary strand from the single-stranded template, the 5' to 3' exonuclease of the polymerase extends the nascent strand through the probe, thereby degrading the probe annealed to the template. Degradation of the probe then releases the fluorophore and destroys its proximity to the quencher, thus relieving the quenching effect and allowing the fluorophore to fluoresce. Thus, the fluorescence detected in a quantitative PCR thermal cycler is directly proportional to the amount of fluorophore released and DNA template present in the PCR.

[0066] Primers and probes are generally 5-100 nucleotides or more in length. In some embodiments, primers and probes can be at least 20 nucleotides or more in length, or at least 25 nucleotides or more, or at least 30 nucleotides or more in length. Such primers and probes specifically hybridize to the target sequence under optimal hybridization conditions known in the art. Primers and probes according to the present invention can have perfect sequence complementarity with the target sequence, but probes that are different from the target sequence and retain the ability to hybridize to the target sequence can be designed by conventional methods according to the present invention.

[0067] Methods for preparing and using probes and primers are described, for example, in Molecular Cloning: A Laboratory Manual, 2nd ed., vol. 1-3, ed. Sambrook et al., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989. PCR-primer pairs can be derived from known sequences, for example, by using computer programs designed for that purpose.

[0068] Polymerase chain reaction (PCR) is a technique for "amplifying" specific fragments of DNA. To perform PCR, at least a portion of the nucleotide sequence of the DNA molecule to be replicated must be known. Generally, primers or short oligonucleotides are used that are complementary (e.g., substantially complementary or completely complementary) to the nucleotide sequence at the 3' end of each strand of the DNA to be amplified (known sequence). The DNA sample is heated to separate its strands and mixed with the primers. The primers hybridize to their complementary sequences in the DNA sample. Synthesis begins (5' to 3' direction) using the original DNA strand as a template. The reaction mixture must contain all four deoxynucleotide triphosphates (dATP, dCTP, dGTP, and dTTP) and DNA polymerase. Polymerization continues until each newly synthesized strand has progressed far enough to contain a sequence recognized by the other primer. When this happens, two DNA molecules are produced that are identical to the original molecule. These two molecules are heated to separate their strands, and the process is repeated. Each cycle doubles the number of DNA molecules. Using automated equipment, each cycle of replication can be completed in less than five minutes. After 30 cycles, what began as a single molecule of DNA has been amplified to more than one billion copies (2 30 =1.02×10 9 ).

[0069] The oligonucleotides of the oligonucleotide primer pair are located on opposite DNA strands and are complementary to DNA sequences that flank the region to be amplified. The annealed primers hybridize to the newly synthesized DNA strands. The first amplification cycle results in two new DNA strands whose 5' ends are fixed by the position of the oligonucleotide primers, but whose 3' ends are variable (ragged 3' ends). The two new strands can then serve as templates for the synthesis of complementary strands of the desired length (the 5' ends are defined by the primers, and the 3' ends are fixed because synthesis cannot proceed beyond the end of the opposing primer). After several cycles, products of the desired fixed length begin to predominate.

[0070] Quantitative polymerase chain reaction (qPCR), also called real-time polymerase chain reaction, monitors the accumulation of DNA products from a PCR reaction in real time. qPCR is a molecular biology laboratory technique based on the polymerase chain reaction (PCR) and is used to amplify and simultaneously quantify target DNA molecules. Even one copy of a specific sequence can be amplified and detected in PCR. The PCR reaction exponentially produces copies of the DNA template. This results in a quantitative relationship between the amount of starting target sequence and the amount of PCR product accumulated in any particular cycle. Due to inhibitors of the polymerase reaction found in the template, reagent limitation, or accumulation of pyrophosphate molecules, the PCR reaction eventually stops producing template at an exponential rate (i.e., plateau phase), making end-point quantification of PCR products unreliable. Thus, overlapping reactions may produce variable amounts of PCR products. Only during the exponential phase of the PCR reaction is it possible to extrapolate back to determine the starting amount of template sequence. Measurement of PCR products as they accumulate (i.e., real-time quantitative PCR) allows quantification in the exponential phase of the reaction, thus eliminating the variability associated with conventional PCR. In a real-time PCR assay, a positive reaction is detected by the accumulation of a fluorescent signal. Quantitative PCR allows both detection and quantification of one or more specific sequences in a DNA sample. This amount can be either an absolute number of copies, or a relative amount when normalized to the DNA input, or to an additional normalizing gene. Since the first documentation of real-time PCR, it has been used in an increasing and diverse number of applications, including mRNA expression studies, DNA copy number measurements in genomic or viral DNA, allelic discrimination assays, expression analysis of specific splice variants of genes, and gene expression in paraffin-embedded tissues and laser capture microdissected cells.

[0071] As used herein, the expression "Ct value" refers to the "threshold cycle", which is defined as the fractional cycle number at which the amount of amplified target reaches a fixed threshold value. In some embodiments, this represents the intersection of the amplification curve with a threshold line. The amplification curve is typically an "S" shape showing the change in relative fluorescence (Y-axis) of each reaction at a given cycle (X-axis), which in some embodiments is recorded during PCR by a real-time PCR instrument. The threshold line, in some embodiments, is the level of detection at which the reaction reaches a fluorescence intensity above background. See Livak & Schmittgen (2001) 25 Methods 402-408. This is a relative measure of the concentration of the target in PCR. In general, good Ct values ​​for quantitative assays such as qPCR are in some embodiments in the range of 10-40 for a given reference gene. The Ct level is inversely proportional to the amount of target nucleic acid in the sample (i.e., the lower the Ct level, the greater the amount of detectable target nucleic acid in the sample). In addition, a good Ct value for a quantitative assay such as qPCR exhibits a linear response range at proportional dilutions of the target gDNA.

[0072] In some embodiments, qPCR is carried out under conditions that allow Ct values ​​to be collected in real time for quantitative analysis.For example, in a typical qPCR experiment, DNA amplification is monitored at each cycle of PCR during the extension stage.When DNA is in the log-linear phase of amplification, the amount of fluorescence generally increases above background.In some embodiments, Ct values ​​are collected at this point.

[0073] As used herein, the term "cell" refers to any living cell. The cell may be a prokaryotic or eukaryotic cell. The cell may be isolated. The cell may or may not be capable of regenerating into an organism. The cell may be in the form of a tissue, callus, culture, organ, or part. In some embodiments, the cell may be a plant cell. The plant cell of the present invention may be in the form of an isolated single cell, or may be a cultured cell, or may be part of a more highly organized unit, such as a plant tissue or plant organ. The plant cell may be derived from or part of an angiosperm or gymnosperm. In further embodiments, the plant cell may be a monocotyledonous plant cell, a dicotyledonous plant cell. The monocotyledonous plant cell may be, for example, a corn, rice, sorghum, sugarcane, barley, wheat, oat, turfgrass, or ornamental grass cell. The dicotyledonous plant cell may be, for example, a tobacco, pepper, eggplant, sunflower, cruciferous, flax, potato, cotton, soybean, sugar beet, or rape cell.

[0074] The term "plant part", as used herein, includes, but is not limited to, embryo, pollen, ovule, seed, leaf, stem, shoot, flower, branch, fruit, grain, ear, cob, husk, stalk, root, root tip, anther, plant cell, including plant cells intact in a plant and / or plant part, plant protoplast, plant tissue, plant cell tissue culture, plant callus, plant mass, etc. As used herein, "shoot" refers to the above-ground part including leaves and stem. Additionally, as used herein, "plant cell" refers to the structural and physiological unit of a plant, including the cell wall, which may also be referred to as a protoplast.

[0075] The term "introducing" or "introducing" in the context of a cell, a prokaryotic cell, a bacterial cell, a eukaryotic cell, a plant cell, a plant and / or a plant part means contacting a nucleic acid molecule with a cell, a eukaryotic cell, a plant, a plant part and / or a plant cell such that the nucleic acid molecule gains access to the interior of the cell, the eukaryotic cell, the plant cell and / or the cell of the plant and / or the plant part. When more than one nucleic acid molecule is introduced, the nucleic acid molecules may be assembled as part of a single polynucleotide or nucleic acid construct or as separate polynucleotides or nucleic acid constructs and may be located on the same or different nucleic acid constructs. Thus, the polynucleotides may be introduced into the plant cell in a single transformation event, in separate transformation events, or as part of, for example, a breeding protocol.

[0076] An "inversion" is a chromosomal rearrangement in which a segment of a chromosome is flipped end-to-end. Inversions occur when a single chromosome undergoes a break and rearranges within itself. A chromosomal "translocation" is a rearrangement of parts between non-homologous chromosomes.

[0077] As used herein, the terms "transformed" and "transgenic" refer to any cell, prokaryotic cell, eukaryotic cell, plant, plant cell, callus, plant tissue, or plant part that contains all or a portion of at least one recombinant (e.g., heterologous) polynucleotide. In some embodiments, all or a portion of the recombinant polynucleotide is stably integrated into a chromosome or a stable extrachromosomal element, and is thereby passed on to successive generations. For purposes of the present invention, the term "recombinant polynucleotide" refers to a polynucleotide that has been altered, rearranged, or modified by genetic engineering. Examples include any cloned polynucleotide, or a polynucleotide that is joined or linked to a heterologous sequence. The term "recombinant" does not refer to changes in a polynucleotide that result from naturally occurring events, such as spontaneous mutations, or from non-naturally occurring mutagenesis followed by selective breeding.

[0078] The term "transformation" as used herein refers to the introduction of heterologous nucleic acid into a cell. Transformation of a cell may be stable or transient. Thus, the transgenic cells, plant cells, plants and / or plant parts of the present invention may be stably transformed or transiently transformed. Transformation may refer to the transfer of a nucleic acid molecule into the genome of a host cell, resulting in genetically stable inheritance. In some embodiments, introduction into the plant, plant part and / or plant cell is via bacterial mediated transformation, particle bombardment transformation, calcium phosphate mediated transformation, cyclodextrin mediated transformation, electroporation, liposome mediated transformation, nanoparticle mediated transformation, polymer mediated transformation, virus mediated nucleic acid delivery, whisker mediated nucleic acid delivery, microinjection, sonication, infiltration, polyethylene glycol mediated transformation, protoplast transformation, or any other electrical, chemical, physical and / or biological mechanism that results in the introduction of a nucleic acid into the plant, plant part and / or cell thereof, or any combination thereof.

[0079] The procedures for transforming plants are well known and routine in the art and are described throughout the literature.Non-limiting examples of methods for transforming plants include bacterial-mediated nucleic acid delivery (e.g., via bacteria from the genus Agrobacterium), virus-mediated nucleic acid delivery, silicon carbide or nucleic acid whisker-mediated nucleic acid delivery, liposome-mediated nucleic acid delivery, microinjection, microparticle bombardment, calcium phosphate-mediated transformation, cyclodextrin-mediated transformation, electroporation, nanoparticle-mediated transformation, sonication, infiltration, PEG-mediated nucleic acid uptake, and transformation via any other electrical, chemical, physical (mechanical) and / or biological mechanism (including any combination thereof) that results in the introduction of nucleic acid into plant cells. General guides to various plant transformation methods known in the art include Miki et al. ("Procedures for Introducing Foreign DNA into Plants" in Methods in Plant Molecular Biology and Biotechnology, Glick, B R and Thompson, J E, Eds. (CRC Press, Inc., Boca Raton, 1993), pages 67-88) and Rakowoczy-Trojanowska (Cell Mol Biol Lett 7:849-858 (2002)).

[0080] Agrobacterium-mediated transformation is a commonly used method for transforming plants because of the high efficiency of transformation and its broad utility with many different species. Agrobacterium-mediated transformation typically involves the introduction of a binary vector carrying the foreign DNA of interest into an appropriate Agrobacterium strain, which may depend on the complement of vir genes carried by the host Agrobacterium strain either on a coexisting Ti plasmid or on the chromosome (Uknes et al. 1993, Plant Cell 5:159-169). The introduction of the recombinant binary vector into Agrobacterium can be achieved by a triparental mating procedure using Escherichia coli carrying the recombinant binary vector, a helper E. coli strain carrying a plasmid capable of mobilizing the recombinant binary vector into the target Agrobacterium strain. Alternatively, the recombinant binary vector can be introduced into Agrobacterium by nucleic acid transformation (Hoefgen and Willmitzer 1988, Nucleic Acids Res 16:9877).

[0081] Transformation of plants with recombinant Agrobacterium usually involves co-cultivation of the Agrobacterium with explants from the plant, following methods well known in the art. Transformed tissues are typically regenerated on selective media that carry an antibiotic or herbicide resistance marker between the binary plasmid T-DNA borders.

[0082] Another method for transforming plants, plant parts and plant cells involves propelling inert or biologically active particles in plant tissues and cells. See, for example, U.S. Patent Nos. 4,945,050, 5,036,006 and 5,100,792. In general, the method involves propelling inert or biologically active particles in plant cells under conditions effective to penetrate the outer surface of the cell and incorporate into its interior. When inert particles are utilized, a vector can be introduced into the cell by coating the particle with the vector containing the nucleic acid of interest. Alternatively, one or more cells can be surrounded by the vector, such that the vector is carried into the cell by the wake of the particle. Biologically active particles (e.g., dried yeast cells, dried bacteria or bacteriophage, each containing one or more nucleic acids desired to be introduced) can also be propelled into the plant tissue.

[0083] "Transient transformation" in the context of a polynucleotide means that the polynucleotide is introduced into a cell and does not integrate into the genome of the cell.

[0084] As used herein, in the context of a polynucleotide introduced into a cell, "stably introduce," "stably introduced," "stable transformation," or "stably transformed" means that the introduced polynucleotide is stably integrated into the genome of the cell, and thus the cell is stably transformed with the polynucleotide. Thus, the integrated polynucleotide can be inherited by its progeny, and more particularly, by progeny of multiple successive generations. As used herein, "genome" includes nuclear and / or plastid genomes, and thus includes, for example, integration of a polynucleotide into a chloroplast genome. As used herein, stable transformation also refers to a polynucleotide that is maintained extrachromosomally (e.g., a minichromosome).

[0085] Transient transformation can be detected, for example, by enzyme-linked immunosorbent assay (ELISA) or Western blot, which can detect the presence of peptides or polypeptides encoded by one or more nucleic acid molecules introduced into the organism. Stable transformation of cells can be detected, for example, by Southern blot hybridization assay of the genomic DNA of the cells with a nucleic acid sequence that specifically hybridizes with the nucleotide sequence of the nucleic acid molecule introduced into the organism (e.g., a plant). Stable transformation of cells can be detected, for example, by Northern blot hybridization assay of the RNA of the cells with a nucleic acid sequence that specifically hybridizes with the nucleotide sequence of the nucleic acid molecule introduced into the plant or other organism. Stable transformation of cells can also be detected, for example, by polymerase chain reaction (PCR) or other amplification reactions well known in the art, using specific primer sequences that hybridize with the target sequence of the nucleic acid molecule, resulting in amplification of the target sequence, which can be detected according to standard methods. Transformation can also be detected by direct sequencing and / or hybridization protocols well known in the art.

[0086] Thus, in certain embodiments of the invention, plant cells can be transformed by any method known in the art and as described herein, and intact plants can be regenerated from these transformed cells using any of a variety of known techniques. Plant regeneration from plant cells, plant tissue cultures and / or cultured protoplasts is described, for example, in Evans et al. (Handbook of Plant Cell Cultures, Vol. 1, MacMilan Publishing Co. New York (1983)); and Vasil IR (ed.) (Cell Culture and Somatic Cell Genetics of Plants, Acad. Press, Orlando, Vol. I (1984), and Vol. II (1986)). Methods for selecting transformed transgenic plants, plant cells, and / or plant tissue cultures are routine in the art and can be used in the methods of the invention provided herein.

[0087] "Transformation and regeneration process" refers to the process of stably introducing a transgene into a plant cell and regenerating a plant from the transgenic plant cell. As used herein, transformation and regeneration includes a selection process in which the transgene contains a selection marker and the transformed cells incorporate and express the transgene so that the transformed cells survive and developmentally reproduce in the presence of a selection agent. "Regeneration" refers to the growth of an entire plant from a plant cell, a group of plant cells, or a plant piece, such as a protoplast, callus, or tissue portion.

[0088] The terms "nucleotide sequence", "nucleic acid", "nucleic acid sequence", "nucleic acid molecule", "oligonucleotide" and "polynucleotide" are used interchangeably herein to refer to heteropolymers of nucleotides and include both RNA and DNA, including cDNA, genomic DNA, mRNA, synthetic (e.g., chemically synthesized) DNA or RNA, and chimeras of RNA and DNA. The term nucleic acid molecule refers to a chain of nucleotides regardless of the length of the chain. A nucleotide comprises a sugar, a phosphate, and a base, which is either a purine or a pyrimidine. A nucleic acid molecule can be double-stranded or single-stranded. If single-stranded, the nucleic acid molecule can be a sense strand or an antisense strand. A nucleic acid molecule can be synthesized using oligonucleotide analogs or derivatives (e.g., inosine or phosphorothioate nucleotides). Such oligonucleotides can be used, for example, to prepare nucleic acid molecules with altered base-pairing abilities or increased resistance to nucleases. The nucleic acid sequences provided herein are presented in a 5' to 3' orientation from left to right and are represented using the standard code for representing nucleotide characters as set forth in the United States sequencing regulations, 37 CFR §§ 1.821-1.825 and the World Intellectual Property Organization (WIPO) standard ST.25.

[0089] A "nucleic acid fragment" is a fragment of a given nucleic acid molecule. An "RNA fragment" is a fragment of a given RNA molecule. A "DNA fragment" is a fragment of a given DNA molecule. A "nucleic acid fragment" is a fragment of a given nucleic acid molecule, not isolated from the molecule. An "RNA fragment" is a fragment of a given RNA molecule, not isolated from the molecule. A "DNA fragment" is a fragment of a given DNA molecule, not isolated from the molecule. A segment of a polynucleotide can be of any length, for example, at least 5, 10, 15, 20, 25, 30, 40, 50, 75, 100, 150, 200, 300, or 500 or more nucleotides in length. A segment or portion of a guide sequence can be about 50%, 40%, 30%, 20%, 10% of the guide sequence, for example, one-third or less of the guide sequence, for example, 7, 6, 5, 4, 3, or 2 nucleotides in length.

[0090] The term "derived from" in the context of a molecule refers to a molecule that is isolated or created using a parent molecule or information from that parent molecule. For example, the Cas9 single mutant nickase and the Cas9 double mutant null-nuclease are each derived from a wild-type Cas9 protein.

[0091] In higher plants, deoxyribonucleic acid (DNA) is the genetic material, while ribonucleic acid (RNA) is involved in the transfer of the information contained in DNA into proteins. A "genome" is the totality of genetic material contained in each cell of an organism. Unless otherwise indicated, a particular nucleic acid sequence of the present invention also implicitly encompasses its conservatively modified variants (e.g., degenerate codon substitutions) and complementary sequences as well as sequences explicitly indicated. Specifically, degenerate codon substitutions can be achieved by generating sequences in which the third position of one or more selected (or all) codons is replaced with mixed base and / or deoxyinosine residues (Batzer et al., Nucleic Acid Res. 19:5081 (1991); Ohtsuka et al., J. Biol. Chem. 260:2605-2608 (1985); and Rossolini et al., Mol. Cell. Probes 8:91-98 (1994)). The term nucleic acid molecule is used interchangeably with gene, cDNA, and mRNA encoded by a gene.

[0092] "Sequence identity," as used herein, refers to the degree to which two optimally aligned polynucleotide or peptide sequences remain invariant over the entire window of alignment of the components (eg, nucleotides or amino acids). "Identity" can be readily calculated by known methods, including but not limited to those described in Computational Molecular Biology (Lesk, A.M., ed.) Oxford University Press, New York (1988); Biocomputing: Informatics and Genome Projects (Smith, D.W., ed.) Academic Press, New York (1993); Computer Analysis of Sequence Data, Part I (Griffin, A.M., and Griffin, H.G., eds.) Humana Press, New Jersey (1994); Sequence Analysis in Molecular Biology (von Heinje, G., ed.) Academic Press (1987); and Sequence Analysis Primer (Gribskov, M. and Devereux, J., eds.) Stockton Press, New York (1991).

[0093] As used herein, the term "percent sequence identity" or "percent identity" refers to the percentage of identical nucleotides in a linear polynucleotide sequence of a reference ("query") polynucleotide molecule (or its complementary strand) compared to a test ("subject") polynucleotide molecule (or its complementary strand) when the two sequences are optimally aligned. In some embodiments, "percent identity" can refer to the percentage of identical amino acids in an amino acid sequence.

[0094] As used herein, the phrase "substantially identical" in the context of two nucleic acid molecules, nucleotide sequences or protein sequences refers to two or more sequences or subsequences that have at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% nucleotide or amino acid residue identity when compared and aligned for maximum correspondence using one of the following sequence comparison algorithms or as measured by visual inspection. In some embodiments of the invention, the substantial identity exists over a region of the sequence that is at least about 50 to about 150 residues in length. Thus, in some embodiments of the invention, the substantial identity exists over a region of the sequence that is at least about 50, about 60, about 70, about 80, about 90, about 100, about 110, about 120, about 130, about 140, about 150, or more residues in length. In some particular embodiments, the sequences are substantially identical over at least about 150 residues. In further embodiments, the sequences are substantially identical over the entire length of the coding regions. Moreover, in representative embodiments, substantially identical nucleotide or protein sequences perform substantially the same function (e.g., targeting to a specific genomic target, endonucleolytic cleavage of a specific genomic target site).

[0095] For sequence comparison, typically, one sequence serves as a reference sequence to which test sequence is compared.When using sequence comparison algorithm, test sequence and reference sequence are input into computer, subsequence coordinates are designated as necessary, and sequence algorithm program parameters are designated.Then, sequence comparison algorithm calculates the percent sequence identity of test sequence to reference sequence based on designated program parameters.

[0096] Optimal alignment of sequences to align a comparison window is well known to those skilled in the art and can be performed by tools such as the Smith and Waterman local homology algorithm, the Needleman and Wunsch homology alignment algorithm, the Pearson and Lipman search for similarity method, and optionally by computerized implementations of these algorithms such as GAP, BESTFIT, FASTA, and TFASTA available as part of the GCG® Wisconsin Package® (Accelrys Inc., San Diego, CA). The "fractional identity" for an aligned segment of a test sequence and a reference sequence is the number of identical components shared by the two aligned sequences divided by the total number of components in the reference sequence segment (i.e., the entire reference sequence or a smaller defined portion of the reference sequence). The percent sequence identity is expressed as the fractional identity multiplied by 100. The comparison of one or more polynucleotide sequences can be to a full-length polynucleotide sequence or a portion thereof, or to a longer polynucleotide sequence. For purposes of the present invention, "percent identity" can also be determined for translated nucleotide sequences using BLASTX version 2.0, and for polynucleotide sequences using BLASTN version 2.0.

[0097] Software for performing BLAST analysis is publicly available through the National Center for Biotechnology Information. The algorithm involves first identifying high-scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence that, when aligned with words of the same length in a database sequence, match or meet some positive-valued threshold score T. T is referred to as the neighborhood word score threshold (Altschul et al., 1990). These initial neighborhood word hits act as seeds to initiate searches to find longer HSPs containing them. The word hits are then extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using the parameters M (reward score for a pair of matching residues; always >0) and N (penalty score for mismatching residues; always <0) for nucleotide sequences. For amino acid sequences, a scoring matrix is ​​used to calculate the cumulative scores. Extension of the word hits in each direction is stopped when the cumulative alignment score falls off its maximum achieved value by an amount X, or when the cumulative score falls below zero due to the accumulation of one or more negative scoring residue alignments, or when the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation (E) of 10, a cutoff of 100, M=5, N=4, and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a wordlength (W) of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff & Henikoff, Proc. Natl. Acad. Sci. USA 89:10915 (1989)).

[0098] In addition to calculating percent sequence identity, the BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin & Altschul, Proc. Nat'l. Acad. Sci. USA 90:5873-5787 (1993)). One measure of similarity provided by the BLAST algorithm is the minimum sum probability (P(N)), which provides an indication of the probability that a match between two nucleotide or amino acid sequences would occur by chance. For example, a test nucleic acid sequence is considered to be similar to a reference sequence if the minimum sum probability in the comparison between the test nucleotide sequence and the reference nucleotide sequence is less than about 0.1 to less than about 0.001. Thus, in some embodiments of the present invention, the minimum sum probability in the comparison between the test nucleotide sequence and the reference nucleotide sequence is less than about 0.001.

[0099] Two nucleotide sequences can also be considered to be substantially identical if the two sequences hybridize to each other under stringent conditions. In some representative embodiments, two nucleotide sequences considered to be substantially identical hybridize to each other under highly stringent conditions.

[0100] "Stringent hybridization conditions" and "stringent hybridization wash conditions" in the context of nucleic acid hybridization experiments, such as Southern and Northern hybridization, are sequence dependent and are different under different environmental parameters. Extensive guidance for nucleic acid hybridization is found in Tijssen Laboratory Techniques in Biochemistry and Molecular Biology-Hybridization with Nucleic Acid Probes part I chapter 2 "Overview of principles of hybridization and the strategy of nucleic acid probe assays" Elsevier, New York (1993). In general, highly stringent hybridization and wash conditions are those that meet the thermal melting point (T m ) is chosen to be approximately 5°C lower than

[0101] T m is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. Very stringent conditions are the T mAn example of stringent hybridization conditions for hybridization of complementary nucleotide sequences with more than 100 complementary residues on a filter in a Southern or Northern blot is 50% formamide and 1 mg heparin at 42° C., with hybridization occurring overnight. An example of highly stringent washing conditions is 0.15 M NaCl at 72° C. for about 15 minutes. An example of stringent washing conditions is a 0.2× SSC wash at 65° C. for 15 minutes (see Sambrook, below, for a description of SSC buffers). Often, a low stringency wash is performed before a high stringency wash to remove background probe signal. For example, an example of a moderate stringency wash for a duplex of more than 100 nucleotides is 1× SSC at 45° C. for 15 minutes. For example, an example of a low stringency wash for duplexes of more than 100 nucleotides is 4-6x SSC for 15 minutes at 40°C. For short probes (e.g., about 10-50 nucleotides), stringent conditions typically include a salt concentration of less than about 1.0 M Na ion, typically about 0.01-1.0 M Na ion (or other salt) at pH 7.0-8.3, and a temperature typically at least about 30°C. Stringent conditions can also be achieved by the addition of destabilizing agents such as formamide. In general, a signal-to-noise ratio of 2-fold (or higher) than that observed for an unrelated probe in a particular hybridization assay indicates detection of specific hybridization. Nucleotide sequences that do not hybridize to each other under stringent conditions are still substantially identical if the proteins they encode are substantially identical. This can occur, for example, when copies of nucleotide sequences are made using the maximum codon degeneracy permitted by the genetic code.

[0102] The following are examples of sets of hybridization / wash conditions that may be used to clone homologous nucleotide sequences that are substantially identical to a reference nucleotide sequence of the present invention. In one embodiment, the reference nucleotide sequence is washed with 7% sodium dodecyl sulfate (SDS), 0.5 M NaPO at 50° C. 4 In another embodiment, the reference nucleotide sequence is hybridized to a "test" nucleotide sequence in 1 mM EDTA, 2× SSC, 0.1% SDS at 50° C. ... 4 , 1 mM EDTA, washed in 1× SSC, 0.1% SDS at 50° C., or washed in 7% sodium dodecyl sulfate (SDS), 0.5 M NaPO at 50° C. 4 , 1 mM EDTA, and washed in 0.5X SSC, 0.1% SDS at 50° C. In yet a further embodiment, the reference nucleotide sequence is hybridized to a "test" nucleotide sequence in 7% sodium dodecyl sulfate (SDS), 0.5M NaPO at 50° C. 4 , 1 mM EDTA, washed in 0.1× SSC, 0.1% SDS at 50° C., or washed in 7% sodium dodecyl sulfate (SDS), 0.5 M NaPO at 50° C. 4 , hybridized to a "test" nucleotide sequence in 1 mM EDTA, and washed in 0.1X SSC, 0.1% SDS at 65°C.

[0103] An "isolated" nucleic acid molecule or nucleotide sequence or an "isolated" polypeptide is a nucleic acid molecule, nucleotide sequence or polypeptide that exists apart from its natural environment by the hand of man and / or has a different, modified, regulated and / or altered function compared to its function in its natural environment, and thus is not a product of nature. An isolated nucleic acid molecule or isolated polypeptide can exist in a purified form or can exist in a non-native environment (e.g., a recombinant host cell). Thus, for example, with respect to a polynucleotide, the term isolated means that it is separated from the chromosome and / or cell in which it occurs in nature. A polynucleotide is also isolated if it is separated from the chromosome and / or cell in which it occurs in nature and then the genetic context, chromosome, chromosomal location, and / or it is inserted into a cell in which it does not occur in nature. The recombinant nucleic acid molecules and nucleotide sequences of the present invention can be considered "isolated" as defined above.

[0104] Thus, an "isolated nucleic acid molecule" or "isolated nucleotide sequence" is a nucleic acid molecule or nucleotide sequence that is not immediately adjacent to the nucleotide sequences to which it is immediately adjacent (one at the 5' end and one at the 3' end) in the naturally occurring genome of the organism from which it originates. Thus, in one embodiment, an isolated nucleic acid includes some or all of the 5' non-coding (e.g., promoter) sequences immediately adjacent to the coding sequence. Thus, the term includes recombinant nucleic acids that are incorporated, for example, into a vector, an autonomously replicating plasmid or virus, or into the genomic DNA of a prokaryote or eukaryote, or exist as a separate molecule independent of other sequences (e.g., a cDNA or genomic DNA fragment produced by PCR or restriction endonuclease treatment). It also includes recombinant nucleic acids that are part of a hybrid nucleic acid molecule that encodes an additional polypeptide or peptide sequence. An "isolated nucleic acid molecule" or "isolated nucleotide sequence" can also include nucleotide sequences that are derived from and inserted into the same naturally occurring cell type of origin, but that exist in a non-natural state, e.g., in different copy numbers and / or under the control of regulatory sequences that differ from those found in the natural state of the nucleic acid molecule.

[0105] The term "isolated" can further refer to a nucleic acid molecule, nucleotide sequence, polypeptide, peptide, or fragment (e.g., when produced by recombinant DNA technology), or a chemical precursor or other chemical (e.g., when chemically synthesized), that is substantially free of cellular material, viral material, and / or culture medium. Furthermore, an "isolated fragment" is a fragment of a nucleic acid molecule, nucleotide sequence, or polypeptide that is not naturally occurring as a fragment and as such would not be found in the natural state. "Isolated" does not necessarily mean that the preparation is technically pure (homogeneous), but is sufficiently pure to provide the polypeptide or nucleic acid in a form that can be used for its intended purpose.

[0106] In representative embodiments of the invention, "isolated" nucleic acid molecules, nucleotide sequences, and / or polypeptides are at least about 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% (w / w) or more pure. In other embodiments, "isolated" nucleic acids, nucleotide sequences, and / or polypeptides refer to at least about 5-fold, 10-fold, 25-fold, 100-fold, 1000-fold, 10,000-fold, 100,000-fold or more enrichment of nucleic acid (w / w) has been achieved as compared to the starting material.

[0107] A "wild-type" nucleotide sequence or amino acid sequence refers to a naturally occurring ("native") or endogenous nucleotide sequence or amino acid sequence. Thus, for example, a "wild-type mRNA" is an mRNA that occurs naturally in or is endogenous to an organism. A "homologous" nucleotide sequence is a nucleotide sequence that is naturally associated with a host cell into which it is introduced.

[0108] The terms "open reading frame" and "ORF" refer to the amino acid sequence encoded between the translation initiation and termination codons of a coding sequence. The terms "initiation codon" and "termination codon" refer to the unit of three contiguous nucleotides ("codons") in a coding sequence that specify the initiation and chain termination of protein synthesis (mRNA translation), respectively.

[0109] A "promoter" refers to a nucleotide sequence, usually upstream (5') of its coding sequence, which controls the expression of the coding sequence by providing recognition for RNA polymerase and other factors necessary for proper transcription. A "promoter regulatory sequence" consists of proximal and more distal upstream elements. Promoter regulatory sequences affect transcription, RNA processing or stability, or translation of the associated coding sequence. Regulatory sequences include enhancers, promoters, non-translated leader sequences, introns, and polyadenylation signal sequences. These include sequences that may be natural and synthetic sequences, as well as combinations of natural and synthetic sequences. An "enhancer" is a DNA sequence that can stimulate promoter activity and may be a native element of the promoter or a heterologous element inserted to increase the level or tissue specificity of the promoter. Enhancers can operate in both orientations (normal or inverted) and can function when moved either upstream or downstream from the promoter. The meaning of the term "promoter" includes "promoter regulatory sequence".

[0110] "Primary transformant" and "T0 generation" refer to transgenic plants that are the same genetic generation as the tissue originally transformed (i.e., that has not undergone meiosis and fertilization since transformation). "Secondary transformant" and "T1, T2, T3, etc. generations" refer to transgenic plants derived from the primary transformant through one or more meiosis and fertilization cycles. These may be derived by self-fertilization of the primary or secondary transformant, or by crossing the primary or secondary transformant with other transformed or untransformed plants.

[0111] "Transgene" refers to a nucleic acid molecule that is introduced into and stably maintained in a genome by transformation. A transgene may contain at least one expression cassette, typically contains at least two expression cassettes, and may contain ten or more expression cassettes. A transgene may include, for example, a gene that is heterologous or homologous to a gene of a particular plant being transformed. Additionally, a transgene may include a native gene inserted into a non-native organism, or a chimeric gene. The term "endogenous gene" refers to a native gene in its natural location in the genome of an organism. A "foreign" gene refers to a gene not normally found in the host organism, but that is introduced into an organism by gene transfer.

[0112] "Intron" refers to an intervening segment of DNA that is present almost exclusively in eukaryotic genes but is not translated into an amino acid sequence in the gene product. Introns are removed from the premature mRNA through a process called splicing, which leaves the exons intact to form the mRNA. For purposes of the present invention, the definition of the term "intron" includes modifications to the nucleotide sequence of an intron derived from a target gene, provided that the modified intron does not significantly reduce the activity of its associated 5' regulatory sequence.

[0113] "Exon" refers to a portion of DNA that has a coding sequence for a protein or a portion thereof. Exons are separated by intervening non-coding sequences (introns). For purposes of the present invention, the definition of the term "exon" includes modifications to the nucleotide sequence of an exon derived from a target gene, provided that the modified exon does not significantly reduce the activity of its associated 5' regulatory sequence.

[0114] The term "cleavage" or "cleaving" refers to the cleavage of a covalent phosphodiester bond in the ribosylphosphodiester backbone of a polynucleotide. The term "cleavage" or "cleaving" encompasses both single-stranded and double-stranded breaks. Double-stranded breaks can occur as a result of two different single-stranded cleavage events. Cleavage can result in the generation of either blunt ends or staggered ends. A "nuclease cleavage site" or "genomic nuclease cleavage site" is a region of nucleotides that contains a nuclease cleavage sequence that is recognized by a specific nuclease, which acts to cleave the nucleotide sequence of genomic DNA in one or both strands. Such cleavage by a nuclease enzyme initiates DNA repair mechanisms within the cell, which establish an environment for homologous recombination to occur.

[0115] A "donor molecule" or "donor sequence" is a target polynucleotide, typically a nucleotide polymer or oligomer intended for insertion at a target genomic site. The donor sequence may be one or more transgenes, expression cassettes, or nucleotide sequences of interest. The donor molecule may be a single-stranded, partially double-stranded, or double-stranded donor DNA molecule. The donor polynucleotide may be a natural or modified polynucleotide, an RNA-DNA chimera, or a DNA fragment (either a single-stranded or at least partially double-stranded, or fully double-stranded DNA molecule), or a PGR-amplified ssDNA or at least partially dsDNA fragment. In some embodiments, the donor DNA molecule is part of a circularized DNA molecule. A fully double-stranded donor DNA is advantageous because it may provide increased stability, since dsDNA fragments are generally more resistant to nuclease degradation than ssDNA. In some embodiments, the donor polynucleotide molecule can comprise at least about 100, 150, 200, 250, 300, 250, 400, 450, 500, 600, 700, 800, 900, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 7500, 10000, 15,000, or 20,000 nucleotides (including any value within this range not explicitly recited herein). In some embodiments, the donor DNA molecule comprises a heterologous nucleic acid sequence. In some embodiments, the donor DNA molecule comprises at least one expression cassette. In some embodiments, the donor DNA molecule can comprise a transgene comprising at least one expression cassette. In some embodiments, the donor DNA molecule comprises an allelic modification of a gene that is native to the target genome. The allelic modification may include at least one nucleotide insertion, at least one nucleotide deletion, and / or at least one nucleotide substitution. In some embodiments, the allelic modification may include an INDEL. In some embodiments, the donor DNA molecule includes a homology arm to the target genomic site.In some embodiments, the donor DNA molecule comprises at least 100 contiguous nucleotides that are at least 90% identical to a genomic nucleic acid sequence, and can optionally further comprise a heterologous nucleic acid sequence, such as a transgene.

[0116] As used herein, the terms "proximal" or "proximal to" in reference to one or more nucleotide sequences of the invention means immediately adjacent (e.g., with no intervening sequences) or separated by about 1 base to about 500 bases (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 100, 200, 250, 300, 350, 400, 450, or 500 bases) (including any values ​​included within this range but not explicitly recited herein).

[0117] As used herein, the term "guide RNA" or "gRNA" generally refers to an RNA molecule (or collectively a group of RNA molecules) that can bind to a CRISPR system effector, such as a Cas or Cpf1 protein, and assist in targeting the Cas or Cpf1 protein to a specific location within a target polynucleotide (e.g., DNA). The guide RNA of the present invention can be an engineered single RNA molecule (sgRNA), where, for example, the sgRNA comprises a crRNA segment and optionally a tracrRNA segment. The guide RNA of the present invention can also be a dual guide system, where the crRNA and tracrRNA molecules are physically distinct molecules that then interact to form a duplex for recruitment of a CRISPR system effector, such as Cas9, and targeting of the protein to a target polynucleotide.

[0118] As used herein, the term "crRNA" or "crRNA segment" refers to an RNA molecule or a portion of an RNA molecule that includes a polynucleotide targeting guide sequence, a stem sequence involved in protein binding, and optionally a 3'-overhang sequence. A polynucleotide targeting guide sequence is a nucleic acid sequence that is complementary to a sequence in a target DNA. This polynucleotide targeting guide sequence is also referred to as a "protospacer." In other words, the polynucleotide targeting guide sequence of the crRNA molecule of the present invention interacts with the target DNA in a sequence-specific manner through hybridization (i.e., base pairing). Thus, the nucleotide sequence of the polynucleotide targeting guide sequence of a crRNA molecule can vary and determine the location within the target DNA where the DNA guide RNA and the target DNA will interact.

[0119] The polynucleotide targeting guide sequence of the crRNA molecule can be modified (e.g., by genetic engineering) to hybridize to any desired sequence within the target DNA. The polynucleotide targeting guide sequence of the crRNA molecule of the present invention can have a length of about 12 nucleotides to about 100 nucleotides. For example, the polynucleotide targeting guide sequence of the crRNA can have a length of about 12 nucleotides (nt) to about 80 nt, about 12 nt to about 50 nt, about 12 nt to about 40 nt, about 12 nt to about 30 nt, about 12 nt to about 25 nt, about 12 nt to about 20 nt, or about 12 nt to about 19 nt. For example, the DNA-targeting segment of the crRNA of the present invention can have a length of about 17 nt to about 27 nt. For example, the polynucleotide targeting guide sequence of the crRNA can be from about 19 nt to about 20 nt, from about 19 nt to about 25 nt, from about 19 nt to about 30 nt, from about 19 nt to about 35 nt, from about 19 nt to about 40 nt, from about 19 nt to about 45 nt, from about 19 nt to about 50 nt, from about 19 nt to about 60 nt, from about 19 nt to about 70 nt, from about 19 nt to about 80 nt, from about 19 nt to about 90 nt, The nucleotide sequence of the polynucleotide targeting guide sequence of the crRNA may have a length of at least about 12 nt. In some embodiments, the polynucleotide targeting guide sequence of the crRNA is 20 nucleotides in length. In some embodiments, the polynucleotide targeting guide sequence of the crRNA is 19 nucleotides in length.

[0120] The present invention also provides a guide RNA comprising an engineered crRNA, where the crRNA comprises a bait RNA segment capable of hybridizing to a genomic target sequence. The engineered crRNA can be a physically distinct molecule, such as in a dual-guide system.

[0121] As used herein, the term "tracrRNA" or "tracrRNA segment" refers to an RNA molecule or portion thereof that includes a protein-binding segment (e.g., the protein-binding segment can interact with a CRISPR-associated protein, such as Cas9). The present invention also provides a guide RNA that includes an engineered tracrRNA, where the tracrRNA further includes a bait RNA segment that can bind to a donor DNA molecule. The engineered tracrRNA may be a physically distinct molecule, such as in a dual-guide system, or may be a segment of an sgRNA molecule.

[0122] In some embodiments, the guide RNA, either as an sgRNA or as two or more RNA molecules, does not comprise a tracrRNA, as it is known in the art that some CRISPR-associated nucleases, such as Cpf1 (also known as Cas12a), do not require tracrRNA for their RNA-mediated endonuclease activity (Qi et al., 2013, Cell, 152:1173-1183; Zetsche et al., 2015, Cell 163:759-771). Such guide RNAs of the present invention may comprise a crRNA, with a bait RNA operably linked at the 5' or 3' end of the crRNA. Cpf1 also has RNase activity on its cognate pre-crRNA (Fonfara et al., 2016, Nature, doi.org / 10.1038 / nature17945). The guide RNAs of the present invention may comprise multiple crRNAs, as Cpf1 has on mature crRNA. In some embodiments, each of these crRNAs is operably linked to a bait RNA. In other embodiments, at least one of these crRNAs is operably linked to a bait RNA. The bait RNA may be specific to a sequence of interest (SOI), as shown in Figure 1 and described in the Examples herein, or may be a "universal" bait, as shown in Figure 2 and described in the Examples herein, which has a corresponding "universal" prey sequence on the donor DNA molecule.

[0123] The present invention also provides a nucleic acid molecule comprising a nucleic acid sequence encoding a guide RNA of the present invention. The nucleic acid molecule can be a DNA or RNA molecule. In some embodiments, the nucleic acid molecule is circularized. In other embodiments, the nucleic acid molecule is linear. In some embodiments, the nucleic acid molecule is single-stranded, partially double-stranded, or double-stranded. In some embodiments, the nucleic acid molecule is complexed with at least one polypeptide. The polypeptide can have a nucleic acid recognition domain or a nucleic acid binding domain. In some embodiments, the polypeptide is a shuttle for mediating delivery of, for example, the chimeric RNA of the present invention, a nuclease, and optionally a donor molecule. In some embodiments, the polypeptide is a Feldan shuttle (US Patent Publication No. 20160298078, incorporated herein by reference). The nucleic acid molecule can comprise an expression cassette capable of driving expression of the chimeric RNA. The nucleic acid molecule may further comprise an additional expression cassette capable of expressing a nuclease, such as, for example, a CRISPR-associated nuclease. The present invention also provides an expression cassette comprising a nucleic acid sequence encoding a chimeric RNA of the present invention.

[0124] A "site-specific modifying polypeptide" modifies a target DNA (e.g., cleavage or methylation of the target DNA) and / or a polypeptide associated with the target DNA (e.g., methylation or acetylation of a histone tail). A site-specific modifying polypeptide is also referred to herein as a "site-directed polypeptide" or an "RNA-binding site-specific modifying polypeptide." A site-specific modifying polypeptide is either a single RNA molecule or an RNA duplex of at least two RNA molecules, and interacts with a guide RNA that is directed to a DNA sequence (e.g., a chromosomal sequence or an extrachromosomal sequence, such as an episomal sequence, a minicircle sequence, a mitochondrial sequence, a chloroplast sequence, etc.) by virtue of its association with the guide RNA.

[0125] In some cases, the site-specific modified polypeptide is a naturally occurring modified polypeptide. In other cases, the site-specific modified polypeptide is a non-naturally occurring polypeptide (e.g., a chimeric polypeptide or a naturally occurring polypeptide that has been modified, e.g., mutated, deleted, inserted). Exemplary naturally occurring site-specific modified polypeptides are known in the art (see, e.g., Makarova et al., 2017, Cell 168:328-328.e1, and Shmakov et al., 2017, Nat Rev Microbiol 15(3):169-182, both of which are incorporated herein by reference). These naturally occurring polypeptides bind to DNA-targeting RNAs, which are then guided to specific sequences within the target DNA and cleave the target DNA to generate double-stranded breaks.

[0126] A site-specific modified polypeptide comprises two portions, an RNA-binding portion and an active portion. In some embodiments, a site-specific modified polypeptide comprises: (i) an RNA-binding portion that interacts with a DNA-targeting RNA, where the DNA-targeting RNA comprises a nucleotide sequence that is complementary to a sequence in the target DNA; and (ii) an active portion that exhibits a site-specific enzymatic activity (e.g., activity for DNA methylation, activity for DNA cleavage, activity for histone acetylation, activity for histone methylation, etc.), where the site of the enzymatic activity is determined by the DNA-targeting RNA. In other embodiments, a site-specific modified polypeptide comprises: (i) an RNA-binding portion that interacts with a DNA-targeting RNA, where the DNA-targeting RNA comprises a nucleotide sequence that is complementary to a sequence in the target DNA; and (ii) an active portion that modulates transcription in the target DNA (e.g., to increase or decrease transcription), where the site of the regulated transcription in the target DNA is determined by the DNA-targeting RNA.

[0127] In some cases, the site-specific modifying polypeptide has an enzymatic activity that modifies target DNA (e.g., nuclease activity, methyltransferase activity, demethylase activity, DNA repair activity, DNA damage activity, deamination activity, dismutase activity, alkylation activity, depurination activity, oxidation activity, pyrimidine dimer formation activity, integrase activity, transposase activity, recombinase activity, polymerase activity, ligase activity, helicase activity, photolyase activity, or glycosylase activity). In other cases, the site-specific modifying polypeptide has an enzymatic activity (e.g., methyltransferase activity, demethylase activity, acetyltransferase activity, deacetylase activity, kinase activity, phosphatase activity, ubiquitin ligase activity, deubiquitinating activity, adenylating activity, deadenylating activity, SUMOylating activity, deSUMOylating activity, ribosylation activity, deribosylation activity, myristoylating activity or demyristoylating activity) that modifies a polypeptide (e.g., a histone) associated with the target DNA.

[0128] In some cases, different site-specific modification polypeptides, such as different Cas9 proteins (i.e., Cas9 proteins from various species), may be advantageously used in the various provided methods of the invention to take advantage of the different enzymatic properties of the different Cas9 proteins (e.g., for different PAM sequence preferences; for increased or decreased enzymatic activity; for increased or decreased cytotoxicity levels; for altered balance between NHEJ, homologous recombination repair, single-strand breaks, double-strand breaks, etc.). Cas9 proteins from various species (e.g., those disclosed in Shmakov et al., 2017, or polypeptides derived therefrom) may require different PAM sequences in the target DNA. Thus, for the particular Cas9 enzyme selected, the PAM sequence requirements may differ from the 5'-N GG-3' sequence (where N is either A, T, C, or G) known to be required for Cas9 activity. Numerous Cas9 orthologs from a wide variety of species have been identified herein, with the proteins sharing few identical amino acids. All identified Cas9 orthologues have the same domain architecture, with a central HNH endonuclease domain and a split RuvC / RNaseH domain. Cas9 proteins share four key motifs with conserved structures; motifs 1, 2, and 4 are RuvC-like motifs, while motif 3 is an HNH-motif.

[0129] The site-specific modification polypeptide can also be a chimeric and modified Cas9 nuclease. For example, the site-specific modification polypeptide can be a modified Cas9 "base editor". Base editing allows direct and irreversible conversion of one target DNA base to another in a programmable manner without the need for DNA cleavage or donor DNA molecules. For example, Komor et al. (2016, Nature, 533:420-424) teach a Cas9-cytidine deaminase fusion, where Cas9 is also engineered to be inactive and not induce double-stranded DNA breaks. In addition, Gaudelli et al. (2017, Nature, doi:10.1038 / nature24644) teach a catalytically impaired Cas9 fused to tRNA adenosine deaminase, which can mediate the conversion of A / T to G / C in a target DNA sequence. Another class of engineered Cas9 nucleases that can act as site-directed modifying polypeptides in the methods and compositions of the invention are variants that can recognize a wide range of PAM sequences, including NG, GAA, and GAT (Hu et al., 2018, Nature, doi:10.1038 / nature26155).

[0130] Any Cas9 protein, including those naturally occurring and / or mutated or modified from naturally occurring Cas9 proteins, can be used as a site-directed modifying polypeptide in the methods and compositions of the invention. The catalytically active Cas9 nuclease cleaves the target DNA to generate double-stranded breaks. These breaks are then repaired by the cell in one of two ways: non-homologous end joining and homology-directed repair.

[0131] In non-homologous end joining (NHEJ), double-strand breaks are repaired by directly joining the cut ends together. Thus, no new nucleic acid material is inserted into the site, but some nucleic acid material may be lost, resulting in a deletion. In homology-directed repair, a donor DNA molecule with homology to the cut target DNA sequence is used as a template for repair of the cut target DNA sequence, resulting in the transfer of genetic information from the donor polynucleotide to the target DNA. Thus, new nucleic acid material can be inserted / copied into the site. In some cases, the target DNA is contacted with a donor molecule, e.g., a donor DNA molecule. In some cases, the donor DNA molecule is introduced into the cell. In some cases, at least a segment of the donor DNA molecule is integrated into the genome of the cell.

[0132] Modification of target DNA by NHEJ and / or homologous recombination repair results in, for example, gene correction, gene replacement, gene tagging, transgene insertion, nucleotide deletion, gene disruption, gene mutation, etc. Thus, cleavage of DNA by site-specific modifying polypeptides can be used to delete nucleic acid material from a target DNA sequence by cleaving the target DNA sequence and allowing the cell to repair the sequence in the absence of an exogenously provided donor polynucleotide (e.g., to destroy a gene that renders a cell susceptible to infection (e.g., the CCR5 or CXCR4 genes that render T cells susceptible to HIV infection), to remove disease-causing trinucleotide repeat sequences in neurons, to create gene knockouts and mutations as disease models in research, etc.). Thus, the subject methods can be used to knock out genes in target DNA (resulting in a complete lack of transcription or altered transcription) or knock in genetic material at a selected locus. Alternatively, when a DNA-targeting RNA duplex and a site-directed modifying polypeptide are co-administered to a cell having a donor molecule that includes at least one segment having homology to the target DNA sequence, the subject methods can be used to add, i.e., insert or replace, nucleic acid material into the target DNA sequence (e.g., to "knock in" a nucleic acid encoding a protein, siRNA, miRNA, etc.), add tags (e.g., 6xHis, fluorescent proteins (e.g., green fluorescent protein; yellow fluorescent protein, etc.), hemagglutinin (HA), FLAG, etc.), add regulatory sequences to genes (e.g., promoters, polyadenylation signals, internal ribosome entry sequences (IRES), 2A peptides, start codons, stop codons, splice signals, localization signals, etc.), modify nucleic acid sequences (e.g., introduce mutations), etc.Thus, complexes comprising a DNA-targeting RNA duplex and a site-specific modifying polypeptide are useful for any in vitro or in vivo application in which it is desirable to modify DNA in a site-specific or "targeted" manner, e.g., gene knock-out, gene knock-in, gene editing, gene tagging, etc., for use, e.g., in gene therapy to treat disease or as anti-viral, anti-pathogenic, or anti-cancer therapies, generation of genetically modified organisms in agriculture, large-scale production of proteins by cells for therapeutic, diagnostic or research purposes, derivation of iPS cells, biological research, targeting genes of pathogens for deletion or replacement, etc.

[0133] The term "CRISPR-associated protein", "Cas protein", "CRISPR-associated nuclease" or "Cas nuclease" refers to a wild-type Cas protein, a fragment thereof, or a mutant or variant thereof. The term "Cas mutant" or "Cas variant" refers to a protein or polypeptide derivative of a wild-type Cas protein, such as a protein having one or more point mutations, insertions, deletions, truncations, fusion proteins, or combinations thereof. In certain embodiments, a Cas mutant or Cas variant substantially retains the nuclease activity of a Cas protein, such as a Cas9 variant described herein, operably linked to a plant-derived nuclear localization signal (NLS). In certain embodiments, the Cas nuclease is mutated such that one or both nuclease domains are inactive, such as a catalytically dead Cas9 called dCas9, which can still target specific genomic locations but has no endonuclease activity (Qi et al., 2013, Cell, 152:1173-1183, incorporated herein). In some embodiments, the Cas nuclease is mutated to lack some or all of the nuclease activity of its wild-type counterpart. The Cas protein may be Cas9, Cpf1 (Zetsche et al., 2015, Cell, 163:759-771, incorporated herein) or any other CRISPR-associated nuclease.

[0134] a. The present invention provides a method for gene silencing a target gene comprising: introducing into a cell a nuclease capable of site-specific DNA cleavage at a target genomic site, creating two or more double-stranded breaks in a single target gene, selecting cells in which the double-stranded breaks have been repaired with an intervening DNA inversion, and silencing expression of the target gene.

[0135] In some embodiments, the present invention provides the above method, further comprising introducing into the cell a third nucleic acid molecule comprising a nucleotide sequence encoding an anti-silencing polypeptide. In some embodiments, the anti-silencing polypeptide can be provided to the cell. In some embodiments, the anti-silencing protein is a viral silencing suppressor (VSR) or is derived from a viral silencing suppressor (VSR). In further embodiments, the anti-silencing protein is a VSR derived from a plant virus. In further embodiments, the anti-silencing protein is a viral silencing suppressor p19 protein derived from a tombusvirus, such as CymRSV, CIRV, or TBSV. Zhu et al. have recently shown that p19 VSR from Tomato Bushy Stunt Virus co-expressed with guide RNA and Cas9 nuclease improves gene targeting efficiency and / or guide RNA stability in plants (US Patent Publication No. 2016 / 0264982). In some embodiments, the VSR is selected from the group of plant viral proteins including HC-Pro, p14, p38, NS, NS3, CaMV P6, PNS10, P122, 2b, Potex p25, ToRSV CP, P0, and SPMMV P1 (see Csorba et al., 2015, Virology 479-480 p.85-103, incorporated herein by reference).

[0136] In some embodiments, the present invention provides the above method, wherein the second nucleic acid molecule encodes a site-directed modifying polypeptide. In further embodiments, the site-directed modifying polypeptide is a nuclease. In yet further embodiments, the site-directed modifying polypeptide is an endonuclease, such as a meganuclease, a zinc finger nuclease, or a TALEN. In some embodiments, the nuclease is an RNA-guided endonuclease. In further embodiments, the nuclease is a CRISPR-associated nuclease, such as Cas9 or Cpf1, or a mutant of Cas9 or Cpf1, such as a nuclease inactivation mutant, or a fusion of at least one domain of Cas9 or CpfI with at least one domain of a different site-directed modifying polypeptide.

[0137] In some embodiments, the present invention provides the above method, further comprising introducing into the cell a third nucleic acid molecule comprising a nucleotide sequence encoding an anti-silencing polypeptide. In some embodiments, the anti-silencing protein is or is derived from a viral silencing suppressor (VSR). In further embodiments, the anti-silencing protein is a VSR derived from a plant virus. In further embodiments, the anti-silencing protein is a viral silencing suppressor p19 protein derived from a Tombus virus, such as CymRSV, CIRV or TBSV. Zhu et al. have recently shown that p19 VSR from Tomato Bushy Stunt Virus co-expressed with guide RNA and Cas9 nuclease improves gene targeting efficiency and / or guide RNA stability in plants (US Patent Publication No. 2016 / 0264982). In some embodiments, the VSR is selected from the group of plant viral proteins including HC-Pro, p14, p38, NS, NS3, CaMV P6, PNS10, P122, 2b, Potex p25, ToRSV CP, P0, and SPMMV P1 (see Csorba et al., 2015, Virology 479-480 p.85-103, incorporated herein by reference).

[0138] The present disclosure provides a method for reducing expression of a target gene, the method comprising introducing into a cell a nuclease capable of site-specific DNA cleavage at a target genomic site, creating two or more double-stranded breaks in a single target gene, selecting cells in which the double-stranded breaks have been repaired with mediated DNA inversions, and reducing expression of the target gene. In some embodiments, the nuclease is selected from the group consisting of meganuclease (MN), zinc finger nuclease (ZFN), transcription activator-like effector nuclease (TALEN), Cas9 nuclease, Cfp1 nuclease, dCas9-FokI, dCpf1-FokI, chimeric Cas9 / Cpf1-cytidine deaminase, chimeric Cas9 / Cpf1-adenine deaminase, chimeric FEN1-FokI, and Mega-TAL, nickase Cas9 (nCas9), chimeric dCas9 non-FokI nuclease, and dCpf1 non-FokI nuclease. In some embodiments of the method, the double-stranded break in the target gene is located in a promoter, UTR, exon, intron, or gene-gene junction region. These methods can be used when the cell has a haploid, diploid, polyploid, or hexaploid genome. These methods can be used when the target gene is dominant, recessive, or semi-dominant. In some embodiments, the methods can utilize one, two, or more guide sequences. The methods are useful in plant cells, but are applicable to any cell.

[0139] The present disclosure provides a method for rearrangement of chromosomes by genome editing, the method includes generating at least one break in a chromosome by a site-specific nuclease and selecting the chromosome with rearrangement. In some embodiments, the method can utilize a site-specific nuclease selected from the group consisting of meganuclease (MN), zinc finger nuclease (ZFN), transcription activator-like effector nuclease (TALEN), Cas9 nuclease, Cfp1 nuclease, dCas9-FokI, dCpf1-FokI, chimeric Cas9 / Cpf1-cytidine deaminase, chimeric Cas9 / Cpf1-adenine deaminase, chimeric FEN1-FokI, and Mega-TAL, nickase Cas9 (nCas9), chimeric dCas9 non-FokI nuclease, and dCpf1 non-FokI nuclease. In some embodiments of the method, the chromosomal rearrangement comprises a deletion, a duplication, an inversion, or a translocation. In some embodiments of the method, the chromosomal rearrangement causes alteration of gene expression. In some embodiments of the method, the alteration of gene expression comprises regulation at the precursor mRNA level, or at the mature mRNA level, or at the translation level. In some embodiments of the method, the chromosomal rearrangement comprises chromosomes from two species, where the chromosomes can be grouped into one nucleus, such as in an interspecies hybrid. In some embodiments of the method, the chromosomal rearrangement results in new allele generation by fusing at least two alleles or two components from different alleles. In some embodiments of the method, the chromosomal rearrangement targets a promoter, an exon, an intron, or a transcription terminator. In some embodiments of the method, the chromosomal rearrangement causes alteration of gene expression of a different gene that has sequence similarity with the rearranged gene. In further embodiments of the method, the deletion, duplication, inversion, or translocation is 19 base pairs or more.

[0140] The present invention will now be described with reference to the following examples. It should be appreciated that these examples are not intended to limit the scope of the invention claimed, but are intended to illustrate specific embodiments. Any variations in the exemplified methods that occur to those skilled in the art are within the scope of the present invention. EXAMPLES

[0141] Example 1: Gene inversion by gene editing To test gene inversion by gene editing, a target was identified in the genome of rice (Oryza sativa). The target gene is DENSE AND ERECT PANICLE 1 (DEP1, SEQ ID NO: 1). Japonica rice dep1 mutant contains a 625 bp deletion near the 3' end of DEP1. The mutant has a dense and erect panicle with higher kernel number and lower plant height than the wild type (Huang et al., 2009, Nat Genet 41:494-497. Indica rice has a wild type copy of the DEP1 gene. For the examples described herein, DEP1 was targeted for gene inversion by genome editing.

[0142] Binary vector 22603 contained an expression cassette (SEQ ID NO: 2) producing guide RNA-B (gRNA-B, gtccaagctgcggatgcaa, SEQ ID NO: 3) targeting exon 5 of DEP1 and a second expression cassette with gRNA-D (gtgccctgaatgttcctgt, SEQ ID NO: 4) also targeting exon 5. Binary vector 22604 contained an expression cassette (SEQ ID NO: 5) producing guide RNA-A (actgcagtgcgtgctgcgc, SEQ ID NO: 6) and a second expression cassette with gRNA-D, a third expression cassette producing gRNA-B, and a fourth expression cassette producing guide RNA-C (cccaatgcaaacccgattg, SEQ ID NO: 7). All expression cassettes in each binary vector are part of a single transgene.

[0143] All binary vectors described herein contain an expression cassette for expressing the Cas9 endonuclease (WO16106121, which is incorporated herein by reference in its entirety) and a second expression cassette for expressing a selectable marker for transformation.

[0144] Rice (Oryza sativa) inbred line IR58025B was used for Agrobacterium-mediated transformation experiments following protocols for transformation, selection, and regeneration essentially as described in Gui et al. 2014 (Plant Cell Rep 33:1081-1090, incorporated herein by reference). Transgenic rice lines were grown in a greenhouse at 16 h light / 30° C. and 8 h dark / 22° C.

[0145] Leaf tissue from the T0 transgenic events was sampled and used for genomic DNA extraction followed by TaqMan analysis. TaqMan analysis was performed essentially as described in Ingham et al. (Biotechniques 31(1):132-4,136-40,2001) (herein incorporated by reference). TaqMan was performed to detect the presence of the Cas9 gene (Table 1, SEQ ID NOs:9-10 are primers; SEQ ID NO:11 is probe) and a series of TaqMan assay targeting mutations in DEP1 (SEQ ID NOs:12-20). To detect mutations in DEP1, forward and reverse primers flank the protospacer target sequence, and the probe hybridizes to a region of the protospacer that includes the Cas9 cleavage site and the PAM. If a mutation (typically an indel) is introduced at the Cas9 cleavage site, the probe will not bind to the target sequence and therefore will not generate fluorescence (signal 0). Genotypic characterization was based on TaqMan analysis of DEP1 (Table 2).

[0146] [Table 1]

[0147] [Table 2]

[0148] Leaf tissue from the T0 event was sampled and used for genomic DNA extraction. The DEP1 gene fragment was amplified by PCR using primers 5'-AAAGACCAAGGTGCCTCA-3' (SEQ ID NO: 21) and 5'-TGGTTCAACCTCGTCTCATA-3' (SEQ ID NO: 22). PCR products were isolated by target size gel electrophoresis and cloned into pCR-Blunt vector (Invitrogen). 15-30 colonies per amplicon were sequenced using Sanger sequencing with M13 forward and reverse primers located in the pCR-Blunt vector. Sequences were assembled and analyzed by alignment against the wild-type DEP1 sequence using both Vector-NTI Advance 11 (Invitrogen) and BLAST analysis.

[0149] RIET142202A049A and RIET142500B024A are two edits with an inversion in exon 5 (Figure 1). In RIET142202A049A, a 413bp fragment was inverted between gRNA-B and gRNA-D (genomic sequence, SEQ ID NO: 23). In the following expression studies, RIET142202A130A from the same construct 22603 was selected as a control with a 444bp deletion between gRNA-B and gRNA-D (genomic sequence, SEQ ID NO: 24). In the edit from 22604, RIET142500B024A was identified with an inversion between gRNA-A and gRNA-B (genomic sequence, SEQ ID NO: 25). Similarly, RIET142300A014A was selected as an additional expression control (genomic sequence, SEQ ID NO: 26).

[0150] Example 2: Combining mutant DEP1 with wild-type DEP1 To investigate the expression of wild-type DEP1 in the presence of inverted DEP1, a workflow was designed as shown in Figure 2. T1 seeds were collected from self-pollinated T0 plants and then sown in germination trays for 2 weeks in a greenhouse at 16 h light / 30 °C, 8 h dark / 22 °C. Leaf tissue from T1 plants was sampled and used for genomic DNA extraction. Genotyping primers for 14SBC500773 (T1 seeds of RIET142202A130A) were 5'-TCTTTGCTGCTGTTGCAAGT-3' (sense primer, SEQ ID NO: 27) and 5'-TCAACCACTGAGACAGCATGG-3' (antisense primer, SEQ ID NO: 28). PCR products were isolated by gel electrophoresis (Figure 3). A similar process was applied to genotype other events.

[0151] The selected T1 plants were transferred to large pots in the greenhouse under the same conditions (Figure 4). Meanwhile, 58025 wild-type seeds were sown and transferred to large pots in parallel. At the flowering stage, pollen from 58025B wild-type plants was collected and fertilized with homozygous-deleted and inverted plants to generate F1 seeds (Table 3).

[0152] [Table 3]

[0153] Example 3: Comparing the expression of wild-type OsDEP1 Young spikes of 2-3 cm were sampled from F1 plants at the early start-up stage (Figure 5); 5-6 young spikes were sampled from each genotype, and RNA isolation and cDNA synthesis were handled per sample. RNA was isolated by Invitrogen TRIzol™ according to standard protocols, and cDNA was synthesized by Superscript™ III First Strand Synthesis System (Invitrogen). First, we confirmed that the two DEP1 alleles were transcribed in F1 spikes. Sense primers 5'-CTGGAGGTGCAGATCCTGAG-3' (sense primer, located in exon 1, SEQ ID NO: 29) and 5'-CTTCAATGGTTCAACCTCGTC-3' (antisense primer, located in 3'UTR, SEQ ID NO: 30) were used (Figure 6). Using the primer pair, the amplicon from wild type 58025B was 1467 bp in size; in the F1 plants of 17SBC500140, two bands were present, one wild type DEP1 and one DEP1 with a 444 bp deletion. In 17SBC500146 and 17SBC500149, the amplicons were similar in size from the two alleles and had a 102 bp deletion compared to the wild type DEP1 amplicon. The presence of DEP1 transcripts with deletions and inversions was further confirmed by colony sequencing.

[0154] Then, cDNA from each sample was mixed in the same genotype to compare wild-type DEP1 expression between WT / deletion and WT / inversion via semi-qRT-PCR. Rice ubiquitin (Os03g0234200) was selected for expression control with primers 5'-CCAGCAGCGGCTGATCTTC-3' (SEQ ID NO: 31) and 5'-CAGGCGCGCATAGCATGAGAA-3' (SEQ ID NO: 32). A wild-type DEP1 specific primer set, 5'-ATGGGCTGCCACCATGGATAA-3' (SEQ ID NO: 33) and 5'-CAGCTTGGAAGGCCACAG-3' (SEQ ID NO: 34), was designed to amplify. PCR products were isolated by gel electrophoresis and quantified by AlphaImager HP software based on area size. Expression ratio was calculated by dividing the area of ​​wild-type DEP1 band in F1 with inversion by that in F1 with deletion, then adjusted by the expression ratio of ubiquitin control (Figure 7, Table 4). Both types of inversions were able to reduce the expression of wild-type DEP1.

[0155] [Table 4]

[0156] Example 4: Translocation by genome editing The same process as shown in Example 1, E0 plant, RIET142500A084A, was identified with two translocations (Figure 8, SEQ ID NO: 105, SEQ ID NO: 35). Instead of inversion at the same position, there were two fragments released from gRNA-A and -B regions and gRNA-C and -D regions. Part of a gene or the whole gene (including promoter and terminator regions), or multiple genes may be translocated to a nearby new location or to another chromosome. Duplication can be achieved based on the design in Figure 9 by targeting translocation of the whole gene or multiple genes. Expression of genes can be upregulated with more copies. In another aspect, allelic exchange can be achieved through genome editing if the genome forms two species grouped into one nucleus. Duplication with too many copies can also result in gene silencing; like HA412, high oleic sunflower inbreds have three intact copies of HaFAD2-1 but no expression.

[0157] Part of the gene can be translocated to the same region or a new region. In the case of translocation in the same region, partial duplication or hairpin loop structure can be generated (Figure 10). In sunflower, partial duplication of HaFAD2-1 (ODS) silences the intact ODS gene, leading to high oleic acid in the nucleus (Mol Genet Genomics (2009) 281:43-54); this can also silence other wild-type HaFAD2-1 in the generated hybrid. Similar designs can provide non-transgenic gene silencing tools. Similar to TaMLO, edited TaMLO-A can silence the expression of B and D alleles, which can achieve disease resistance, but with a reduced growth penalty in triple mutants (Figure 11). Using the same strategy, paralogs can also be modified in expression. Translocations can also fuse genes, generating new genes or new alleles of the same gene.

Claims

1. a) introducing into a cell a nuclease capable of site-specific DNA cleavage at a target genomic site; b) creating two or more double-stranded breaks in a single target gene; c) selecting cells in which the double strand break has been repaired with an intervening DNA inversion; d) decreasing expression of said target gene; and The method for reducing expression of a target gene, comprising:

2. 2. The method of claim 1, wherein the nuclease is selected from the group consisting of Meganuclease (MN), Zinc Finger Nuclease (ZFN), Transcription Activator-Like Effector Nuclease (TALEN), Cas9 nuclease, Cfp1 nuclease, dCas9-FokI, dCpf1-FokI, chimeric Cas9 / Cpf1-cytidine deaminase, chimeric Cas9 / Cpf1-adenine deaminase, chimeric FEN1-FokI, and Mega-TAL, nickase Cas9 (nCas9), chimeric dCas9 non-FokI nuclease, and dCpf1 non-FokI nuclease.

3. 2. The method of claim 1, wherein the double-stranded break in the target gene is located in a promoter, a UTR, an exon, an intron, or a gene-gene junction region.

4. 2. The method of claim 1, wherein the cell of claim 1 has a haploid, diploid, polyploid, or hexaploid genome.

5. The method of claim 1 , wherein the target gene is recessive or semi-dominant.

6. 10. The method of claim 1, further comprising one or more guide sequences.

7. 7. The method of claim 6, wherein the one or more guide sequences comprise two or more guide sequences.

8. The method of claim 1 , wherein the cell is a plant cell.

9. 1. A method for rearranging chromosomes by genome editing, comprising: a. generating at least one break in the chromosome with a site-specific nuclease; b. Selecting the chromosomes that have a rearrangement; A method comprising:

10. 10. The method of claim 9, wherein the site-specific nuclease is selected from the group consisting of Meganuclease (MN), Zinc Finger Nuclease (ZFN), Transcription Activator-Like Effector Nuclease (TALEN), Cas9 nuclease, Cfp1 nuclease, dCas9-FokI, dCpf1-FokI, chimeric Cas9 / Cpf1-cytidine deaminase, chimeric Cas9 / Cpf1-adenine deaminase, chimeric FEN1-FokI, and Mega-TAL, nickase Cas9 (nCas9), chimeric dCas9 non-FokI nuclease, and dCpf1 non-FokI nuclease.

11. 10. The method of claim 9, wherein the chromosomal rearrangement comprises a deletion, duplication, inversion, or translocation.

12. The method of claim 9 , wherein the chromosomal rearrangement results in altered gene expression.

13. 10. The method of claim 9, wherein the gene expression modification comprises modulation at the precursor mRNA level, or at the mature mRNA level, or at the translation level.

14. 10. The method of claim 9, wherein the chromosomal rearrangement involves chromosomes from two species where the chromosomes can be grouped into one nucleus, such as an interspecies hybrid.

15. 10. The method of claim 9, wherein the chromosomal rearrangement results in the production of a new allele by fusing at least two alleles or two components from different alleles.

16. The method of claim 11, wherein the chromosomal rearrangement targets a promoter, an exon, an intron, or a transcription terminator.

17. 13. The method of claim 12, wherein the chromosomal rearrangement causes altered gene expression of a different gene that has sequence similarity to the rearranged gene.

18. 12. The method of claim 11, wherein the deletion, duplication, inversion, or translocation is 19 base pairs or more.